Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 801

1.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.92. [Epub ahead of print]

PMID:
28322237
2.

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.

Thomas JS, Hanby AM, Russell N, van Tienhoven G, Riddle K, Anderson N, Cameron DA, Bartlett JM, Piper T, Cunningham C, Canney P, Kunkler IH; SUPREMO Trial Management Group..

Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4145-4. [Epub ahead of print]

PMID:
28190252
3.

A single-centre experience of Roux-en-Y enteric drainage for pancreas transplantation.

Amin I, Butler AJ, Defries G, Russell NK, Harper SJ, Jah A, Saeb-Parsy K, Pettigrew GJ, Watson CJ.

Transpl Int. 2017 Apr;30(4):410-419. doi: 10.1111/tri.12920. Epub 2017 Mar 2.

PMID:
28109015
4.

Professor David Grimwade (1962-2016).

Russell NH, Freeman SD, Craddock C.

Bone Marrow Transplant. 2017 Feb;52(2):171-172. doi: 10.1038/bmt.2016.350. Epub 2017 Jan 16. No abstract available.

PMID:
28092352
5.

Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants.

Shaw BE, Mayor NP, Szydlo RM, Bultitude WP, Anthias C, Kirkland K, Perry J, Clark A, Mackinnon S, Marks DI, Pagliuca A, Potter MN, Russell NH, Thomson K, Madrigal JA, Marsh SG.

Bone Marrow Transplant. 2017 Jan 16. doi: 10.1038/bmt.2016.352. [Epub ahead of print]

PMID:
28092349
6.

Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, Bacigalupo A, Socié G, Bonifazi F, Finel H, Velardi A, Potter M, Bruno B, Castagna L, Malladi R, Russell N, Sureda A.

Ann Oncol. 2016 Dec;27(12):2251-2257. doi: 10.1093/annonc/mdw421. Epub 2016 Oct 24.

PMID:
28007754
7.

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.

van Gelder M, de Wreede LC, Bornhäuser M, Niederwieser D, Karas M, Anderson NS, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen JJ, Yakoub-Agha I, Russell NH, Finke J, Schoemans H, Vitek A, Urbano-Ispízua Á, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schönland S, Kröger N, Schetelig J.

Bone Marrow Transplant. 2017 Mar;52(3):372-380. doi: 10.1038/bmt.2016.282. Epub 2016 Dec 12.

PMID:
27941763
8.

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.

Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, Striha A, Henderson R, Kaiser MF, Jenner M, Cook G, Russell NH, Williams C, Pratt G, Kishore B, Lindsay J, Drayson MT, Davies FE, Boyd KD, Owen RG, Jackson GH, Morgan GJ.

Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114.

9.

SCALABLE VISUALIZATION FOR HIGH-DIMENSIONAL SINGLE-CELL DATA.

Kim J, Russell N, Peng J.

Pac Symp Biocomput. 2016;22:623-634.

10.

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

Knapper S, Russell N, Gilkes A, Hills RK, Gale RE, Cavenagh JD, Jones G, Kjeldsen L, Grunwald MR, Thomas I, Konig H, Levis MJ, Burnett AK.

Blood. 2017 Mar 2;129(9):1143-1154. doi: 10.1182/blood-2016-07-730648. Epub 2016 Nov 21.

PMID:
27872058
11.

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.

Ferguson P, Hills RK, Grech A, Betteridge S, Kjeldsen L, Dennis M, Vyas P, Goldstone AH, Milligan D, Clark RE, Russell NH, Craddock C; UK NCRI AML Working Group..

Haematologica. 2016 Nov;101(11):1351-1358. Epub 2016 Aug 18.

12.

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

Khan N, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, Richardson P, Knapper S, Grimwade D, Russell NH, Burnett AK, Freeman SD.

Leukemia. 2016 Nov 15. doi: 10.1038/leu.2016.309. [Epub ahead of print]

PMID:
27795558
13.

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia.

Khan N, Hills RK, Knapper S, Steadman L, Qureshi U, Rector JL, Bradbury C, Russell NH, Vyas P, Burnett AK, Grimwade D, Hole PS, Freeman SD.

PLoS One. 2016 Sep 26;11(9):e0163291. doi: 10.1371/journal.pone.0163291. eCollection 2016 Sep 26.

14.

Pox-Protein Public Private Partnership program and upcoming HIV vaccine efficacy trials.

Russell ND, Marovich MA.

Curr Opin HIV AIDS. 2016 Nov;11(6):614-619.

PMID:
27636503
15.

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

Burnett AK, Russell NH, Hills RK, Kell J, Nielsen OJ, Dennis M, Cahalin P, Pocock C, Ali S, Burns S, Freeman S, Milligan D, Clark RE.

Leukemia. 2017 Feb;31(2):310-317. doi: 10.1038/leu.2016.225. Epub 2016 Sep 2.

16.

Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001-2010: content and utility analysis.

Hawcutt DB, Russell NJ, Maqsood H, Kouranloo K, Gomberg S, Waitt C, Sharp A, Riordan A, Turner MA.

Br J Clin Pharmacol. 2016 Dec;82(6):1601-1612. doi: 10.1111/bcp.13067. Epub 2016 Sep 12.

PMID:
27597136
17.

Quantification of patient-reported outcome measures of radiation-induced skin reactions for use in clinical trial design.

Russell NS, van Werkhoven E, Schagen SB.

Support Care Cancer. 2017 Jan;25(1):67-74. Epub 2016 Aug 24.

PMID:
27554211
18.

Conductive Education as a Method of Stroke Rehabilitation: A Single Blinded Randomised Controlled Feasibility Study.

Bek J, Brown MR, Jutley-Neilson J, Russell NC, Huber PA, Sackley CM.

Stroke Res Treat. 2016;2016:5391598. doi: 10.1155/2016/5391598. Epub 2016 Jun 23.

19.

Predictors of enduring clinical distress in women with breast cancer.

Lo-Fo-Wong DN, de Haes HC, Aaronson NK, van Abbema DL, den Boer MD, van Hezewijk M, Immink M, Kaptein AA, Menke-Pluijmers MB, Reyners AK, Russell NS, Schriek M, Sijtsema S, van Tienhoven G, Sprangers MA.

Breast Cancer Res Treat. 2016 Aug;158(3):563-72. doi: 10.1007/s10549-016-3896-7. Epub 2016 Jul 14.

20.

Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.

Quek L, Otto GW, Garnett C, Lhermitte L, Karamitros D, Stoilova B, Lau IJ, Doondeea J, Usukhbayar B, Kennedy A, Metzner M, Goardon N, Ivey A, Allen C, Gale R, Davies B, Sternberg A, Killick S, Hunter H, Cahalin P, Price A, Carr A, Griffiths M, Virgo P, Mackinnon S, Grimwade D, Freeman S, Russell N, Craddock C, Mead A, Peniket A, Porcher C, Vyas P.

J Exp Med. 2016 Jul 25;213(8):1513-35. doi: 10.1084/jem.20151775. Epub 2016 Jul 4.

Supplemental Content

Loading ...
Support Center